HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 19MAY21:19:09:3119MAY21:19:09:31 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TE SASDATA 9.4 X64_SR12 19MAY21:19:09:3119MAY21:19:09:31 Trial Elements HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000000700000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation ETCD Element Code ELEMENT Description of Element 7TESTRL Rule for Start of Element 38TEENRL Rule for End of Element jTEDUR Planned Duration of Element ¢ HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P301TEFUA Follow up in blinded phase 28 days after last vaccination in blinded phase 1 day before first dose of mRNA-1273 in open-label phase mRNA-1273-P301TEFUB Follow up in open-label phase28 days after last vaccination in open-label phase 730 days after last vaccination in open-label phase P702DmRNA-1273-P301TEPBO Placebo in blinded phase First dose of placebo in blinded phase P28D mRNA-1273-P301TESCREENScreening Informed consent 28 days after element start P28D mRNA-1273-P301TEV mRNA-1273 in blinded phase First dose of mRNA-1273 vaccination in blinded phase P28D mRNA-1273-P301TEVOL mRNA-1273 in open-label phaseFirst dose of mRNA-1273 vaccination in open-label phase P28D